Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults

Phase 2 Terminated 396 enrolled Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

A 24-month, placebo controlled, double dummy, parallel-design outpatient trial in generally healthy elderly men and women who are at risk of becoming frail.

Timeline

Start: 1999-12
Primary completion: 2001-10
Completion: 2001-10

Publications

White HK, Petrie CD, Landschulz W, MacLean D, Taylor A, Lyles K, Wei JY, Hoffman AR, Salvatori R, Ettinger MP, Morey MC, Blackman MR, Merriam GR; Capromorelin Study Group. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab. 2009 Apr;94(4):1198-206. doi: 10.1210/jc.2008-0632. Epub 2009 Jan 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	capromorelin	Small molecule	3 mg	Oral
Subject	capromorelin	Small molecule	10 mg	Oral

Indications

No indication recorded.